Literature DB >> 9218710

Cloning and analysis of MART-1/Melan-A human melanoma antigen promoter regions.

L H Butterfield1, T C Stoll, R Lau, J S Economou.   

Abstract

The MART-1/Melan-A human melanoma tumor antigen can be recognized by T lymphocytes and appears to be involved in tumor regression. To study the transcriptional regulation of this important gene, the 5' untranslated (UT) region of the MART-1/Melan-A gene was cloned and sequenced. Human melanoma cell lines were screened for MART-1/Melan-A mRNA expression. Primer extension and northern analysis were performed to confirm the mRNA size and start site. Several overlapping fragments of 5'UT were isolated from genomic DNA by polymerase chain reaction (PCR) from the previously described sequence for an additional 700 bp upstream. The fragments isolated (ranging from 838 bp to 160 bp in length) were used to drive luciferase reporter gene expression in melanoma and non-melanoma cell lines. Tissue-specific promoter activity was found in a 233-bp fragment of 5' UT with an average index of induction of 35 fold. The 233-bp MART-1/Melan-A promoter does not appear to have cytokine (IL-2, IL-4, IL-7, GM-CSF, TNF-alpha or IFN-gamma) responsive elements when studied in transient transfection assays.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9218710     DOI: 10.1016/s0378-1119(96)00789-5

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  6 in total

1.  Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.

Authors:  Ali R Jazirehi; James S Economou
Journal:  Mol Cancer Ther       Date:  2012-04-24       Impact factor: 6.261

2.  Molecular mechanism of MART-1+/A*0201+ human melanoma resistance to specific CTL-killing despite functional tumor-CTL interaction.

Authors:  Ali R Jazirehi; Stavroula Baritaki; Richard C Koya; Benjamin Bonavida; James S Economou
Journal:  Cancer Res       Date:  2010-12-15       Impact factor: 12.701

3.  MLANA/MART1 and SILV/PMEL17/GP100 are transcriptionally regulated by MITF in melanocytes and melanoma.

Authors:  Jinyan Du; Arlo J Miller; Hans R Widlund; Martin A Horstmann; Sridhar Ramaswamy; David E Fisher
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

4.  Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.

Authors:  Lisa H Butterfield; Begonya Comin-Anduix; Lazar Vujanovic; Yohan Lee; Vivian B Dissette; Jin-Quan Yang; Hong T Vu; Elizabeth Seja; Denise K Oseguera; Douglas M Potter; John A Glaspy; James S Economou; Antoni Ribas
Journal:  J Immunother       Date:  2008-04       Impact factor: 4.456

5.  Overexpression of meloe gene in melanomas is controlled both by specific transcription factors and hypomethylation.

Authors:  Mathilde Bobinet; Virginie Vignard; Laetitia Florenceau; Francois Lang; Nathalie Labarriere; Agnès Moreau-Aubry
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

6.  The melanoma antigens MELOE-1 and MELOE-2 are translated from a bona fide polycistronic mRNA containing functional IRES sequences.

Authors:  Delphine Carbonnelle; Virginie Vignard; Delphine Sehedic; Agnes Moreau-Aubry; Laetitia Florenceau; Maud Charpentier; Wolfgang Mikulits; Nathalie Labarriere; François Lang
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.